Leading Pharmaceutical Innovation: How to Win the Life Science RaceSpringer, 10. maj 2018 - 179 sider Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia. |
Indhold
1 | |
The Industry Challenge Who Would Want to Be in This Business? | 17 |
The Science and Technology Challenge How to Find New Drugs | 41 |
The Pipeline Challenge How to Organize Innovation | 63 |
The MakeorBuy Challenge How to In and Outsource Innovation | 79 |
The Open Innovation Challenge How to Partner for Innovation | 111 |
The Internationalization Challenge Where to Access Innovation | 135 |
Future Directions and Trends | 155 |
Glossary | 165 |
171 | |
177 | |
Andre udgaver - Se alle
Almindelige termer og sætninger
activities Aliskiren Allergan Amgen approval AstraZeneca Bayer billion biological biomarkers biotech biotechnology biotechnology companies blockbuster blockbuster drugs business models cancer cells challenges chemical China clinical development clinical trials co-development collaboration combinatorial chemistry commercialization complex compounds costs crowdsourcing Debiopharm disease drug candidates drug development drug discovery drug projects drug targets Eli Lilly external gene genetic genome GlaxoSmithKline global growth healthcare in-licensing increase intellectual property internal investments know-how Leading Pharmaceutical licensing manufacturing medicines Merck Novartis oncology open innovation option orphan drug out-licensing outsourcing overall Pantoprazole partners partnership patent protection Pfizer pharma companies pharmaceutical companies pharmaceutical industry pharmaceutical innovation pharmaceutical products pharmaceutical R&D pharmacogenetics phase portfolio potential preclinical protein proteomics R&D center R&D organization R&D pipeline R&D process R&D projects regulatory revenues risk Roche screening sector Shanghai Source Speedel strategy substance success therapeutic areas therapies Venture Fund worldwide